Connect with us
European Gaming Congress 2024

Latest News

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Published

on

  • Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas.
  • Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD, and double-digit royalties on annual sales
  • Additionally, Takeda will purchase a minority interest in Ascentage Pharma

ROCKVILLE, Md. and SUZHOU, China, June 14, 2024 /PRNewswire/ — Ascentage Pharma (6855 HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib in all territories outside of among others, mainland China, Hong Kong, Macau, Taiwan, China.

Despite the impact TKIs have had in the treatment of patients with CML, there remains a significant unmet need for patients whose disease is resistant to these therapies or who develop hard-to-treat mutations following these treatments.

Under the terms of this option agreement, Ascentage Pharma is set to receive 100 million USD from Takeda to acquire the option to license olverembatinib. Ascentage will also be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD. Additionally, Ascentage Pharma is expected to receive a minority equity investment from Takeda.

As part of the agreement, Ascentage Pharma will continue to be solely responsible for all clinical development of olverembatinib before the potential exercise of the option to license olverembatinib. Olverembatinib is currently approved and marketed in China for the treatment of adult patients with TKI-resistant chronic-phase CML (CP-CML) or accelerated-phase CML (AP-CML) harboring the T315I mutation, and in adult patients with CP-CML resistant to and/or intolerant of first-and second-generation TKIs.

“We are thrilled to enter into this agreement with Takeda, which would allow us to leverage the global commercial expertise of an organization with a proven track record and global oncology footprint to potentially broaden the impact olverembatinib could have on patients in need around the world,” said Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma. “Olverembatinib has already had a significant impact for patients with CML in China. We are excited to further the development of olverembatinib in our ongoing global registrational Phase 3 studies.”

“Throughout our history in oncology, Takeda has demonstrated a strong track record of working with companies that share our vision of bringing medicines to patients around the world with the highest unmet needs,” said Teresa Bitetti, president of Takeda’s Global Oncology Business Unit. “Through this agreement with Ascentage Pharma, we believe there is great potential to continue to advance this mission. We are highly encouraged by the promising results olverembatinib has shown in the clinic to date, and excited to have the opportunity to further develop and deliver it to patients with chronic myeloid leukemia and other hematological cancers.”

Advertisement
Stake.com

About Olverembatinib

Olverembatinib, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug has been included in the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates.

Investors Contacts:[email protected]
Media Contacts:PR@ ascentage.com

Advertisement
Stake.com

Forward-Looking Statements

The forward-looking statements in this article relate only to the events or information as of the date on which the statements are made. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Logo – https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/ascentage-pharma-signs-option-agreement-with-takeda-to-enter-into-exclusive-global-license-for-olverembatinib-a-third-generation-bcr-abl-tyrosine-kinase-inhibitor-tki-302173072.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

China remains stabilizing force for global economic growth

Published

on

BEIJING, July 20, 2024 /PRNewswire/ — A report from People’s Daily: In the first six months of this year, China’s economy continued its recovery trend and maintained steady progress.

On July 16, the International Monetary Fund (IMF) released an update to its World Economic Outlook, predicting that China’s economic growth rate will be 5 percent in 2024, an upward revision of 0.4 percentage points from the forecast in April.

The stable operation and long-term positive outlook of the Chinese economy have also boosted confidence in global economic recovery.

The IMF believes that Asia’s emerging market economies, represented by countries including China, remain the main engine of the global economy.

China’s economic growth is not only quantitative but also qualitative.

Advertisement
Stake.com

In the first half of this year, China’s gross domestic product (GDP) grew 5 percent year on year to around 61.7 trillion yuan ($8.49 trillion).

During the period, the country’s total retail sales of consumer goods went up 3.7 percent year on year, with retail sales of services expanding 7.5 percent; investment in infrastructure construction rose 5.4 percent from a year ago while manufacturing investment increased 9.5 percent, signaling burgeoning recovery; and the foreign trade reached a new high, with the goods trade volume reaching 21.2 trillion yuan.

From a medium to long-term perspective, the economic fundamentals that sustain China’s long-term growth remain unchanged, and the trend toward high-quality development in China’s economy has not changed.

China continues to be an important engine and stabilizing force for the world economy.

Facing complex and volatile domestic and international environments, China has maintained stable expansion of its economy and pushed forward industrial upgrading and high-quality development in an orderly manner, spurring the pursuit of high value-added and sustainable economic growth.

Advertisement
Stake.com

Positive factors driving China’s economic transformation, upgrading, and high-quality development have continued to accumulate.

For instance, the country’s output of smart and green products, such as integrated circuits, service robots, new energy vehicles, and solar panels has maintained double-digit growth in the first half of this year.

Besides, the emergence of new consumption scenarios spawned by new technologies like big data and artificial intelligence as well as new consumption models has driven an 8.8 percent year-on-year increase in China’s online retail sales of physical goods during the period.

Meanwhile, China’s energy consumption per unit of GDP has continued to decline.

“With the global economy facing uncertainties and challenges, China’s role as a stabilizing force is more crucial than ever,” pointed out a recent article by Zamir Ahmed Awan, founding chair of Pakistani think tank Global Silk Route Research Alliance.

Advertisement
Stake.com

China’s efforts to deepen reforms across the board have injected strong momentum into the country’s high-quality development and pursuit of Chinese modernization.

Since the 18th National Congress of the Communist Party of China (CPC), China has deepened reforms across the board, with efforts concentrated on making reform more systemic, holistic, and coordinated and on stimulating the dynamism, vitality, and potential of high-quality development.

International observers have paid close attention to the third plenary session of the 20th CPC Central Committee. They believe that China’s economy is undergoing a transition from old to new drivers of growth, and that a smooth transition can be guaranteed by further deepening reforms in a comprehensive manner.

Iqbal Survé, chairman of South Africa’s Independent Media, pointed out that China is building a modern industrial system underpinned by advanced manufacturing and pushing forward reforms, which demonstrates the CPC’s foresight, wisdom, courage, and resolve.

By solidly promoting high-standard opening up, China has opened up vast space for economic development.

Advertisement
Stake.com

During the first six months of this year, China has for the first time released a negative list for cross-border trade in services at the national level, expanded the opening up of value-added telecom services within pilot areas, and introduced new measures to encourage overseas institutions to invest in China’s domestic sci-tech enterprises…

Such policies and measures have demonstrated the country’s resolve to promote reforms and development through opening up.

China is the main trading partner of over 140 countries and regions, with its total volume of foreign trade in goods ranking first globally for seven consecutive years.

China has expanded its circle of friends under the Belt and Road Initiative (BRI) to include more than 150 countries and 30 international organizations, and the ChinaEurope freight train service now reaches over 200 cities in 25 European countries.

In addition, international exhibitions hosted by the country, such as China International Import Expo, China International Fair for Trade in Services, China International Consumer Products Expo, and China International Supply Chain Expo, have served as win-win platforms for mutually beneficial cooperation across different countries.

Advertisement
Stake.com

A prosperous China not only sustains its own future but also provides opportunities for other countries, said an article published on the website of Argentine newspaper Clarin.

The Chinese economy is overcoming challenges and moving steadily forward along the country’s path of high-quality development, which is a defining feature of Chinese modernization.

Looking forward, China will provide more opportunities for countries worldwide and contribute to the stable and sound development of the global economy as it continuously marches toward modernization.

View original content:https://www.prnewswire.co.uk/news-releases/china-remains-stabilizing-force-for-global-economic-growth-302202087.html

Advertisement
Stake.com
Continue Reading

Latest News

RoboSense Sales Volume of LiDAR for ADAS Achieved 487.7% YOY Growth in H1 2024

Published

on

HONG KONG, July 19, 2024 /PRNewswire/ — Recently, RoboSense announced its business progress for the first half year of 2024, demonstrating a high-growth trajectory and maintaining its leadership in the global market. For the six months ended June 30, 2024, RoboSense’s sales volume of LiDAR products and LiDAR products for ADAS applications amounted to approximately 243,400 and 234,500 units, separately reflecting a year-on-year increase of 415.7% and 487.7%.

As OEMs rapidly pursued advancements in intelligent technology, RoboSense achieved nearly its 2023 annual sales volume in the first half year of 2024. RoboSense and the global automotive industry’s intelligent upgrade are progressing and succeeding together. This exponential growth underscores RoboSense’s exceptional capabilities in technological innovation and market expansion, reinforcing our trajectory of outstanding growth as an industry leader.

As of June 30, 2024, RoboSense’s cumulative sales volume of LiDAR have reached approximately 583,500 units, with LiDAR for ADAS approximately 518,300 units. Since pioneering the mass production of LiDAR for ADAS in 2021, RoboSense has demonstrated significant growth, with steadily increasing sales that continue to lead the industry’s development.

Leveraging its powerful LiDAR hardware and perception software technology, as well as leading product performance, RoboSense has made remarkable progress in obtaining vehicle model designs and achieving mass production for various vehicle models. As of May 17, 2024, we have received mass production designation orders for 71 vehicle models from 22 global OEMs and Tier 1 customers. By the end of the first quarter of 2024, we have achieved SOP 25 vehicle models from 12 of these customers.

At the 2024 Auto Beijing Show, RoboSense ranked No.1 with equipment for 37 models, and its occupation was over 50%. As more collaborative vehicle models launch and reach mass production, RoboSense repeatedly shatters records.

Advertisement
Stake.com

In technological innovation and product development, RoboSense continues to launch powerful and technologically advanced products that drive industry progress. In 2024 Q2 and Q3, RoboSense launched the M3, a long-range LiDAR, and the MX, a medium-range LiDAR. In particular, MX gained three new mass production projects shortly after its release, and is expected to realize its first mass production in 2025.

Photo – https://mma.prnewswire.com/media/2465085/RoboSense.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/robosense-sales-volume-of-lidar-for-adas-achieved-487-7-yoy-growth-in-h1-2024–302201601.html

Continue Reading

Latest News

KuCoin Introduces Omnibus Account Structure to Enhance Liquidity for Brokerage Partners

Published

on

VICTORIA, Seychelles, July 19, 2024 /PRNewswire/ — July 23, 2024 – KuCoin, a leading cryptocurrency exchange, is pleased to announce a significant enhancement to its Broker Program, designed to cater to liquidity-seeking partners. This upgraded program enables participants to leverage KuCoin’s superior liquidity and diverse asset offerings across both Spot and Futures markets. With this enhancement, participants can now benefit from KuCoin’s top-tier liquidity, high-revenue shares, unlimited sub-accounts, and independent deposit addresses, allowing for functional flexibility and maintaining their own client management powers.

“Our new brokerage infrastructure is suitable for multiple types of institutional partners, such as crypto exchanges, execution terminals, layer 2 aggregators, OTCs, and traditional financial service providers venturing into crypto,” said Anton Starchenko, Director of Institution Business Development of KuCoin. 

“This upgrade demonstrates our commitment to providing our partners with the tools they need to succeed in the rapidly evolving crypto market.”

By joining the KuCoin brokerage service, brokers gain access to one main broker account with unlimited sub-accounts. Each sub-account features an exclusive deposit address, serving as a wallet to separate funds and trades. Additionally, each sub-account undergoes independent risk checks. These ongoing risk and compliance measures bolster KuCoin’s commitment to protecting partner interests. Broker accounts are subject to separate fee structures, while the broker receives a combined commission based on the cumulative volume across all accounts.

As a leading platform in the cryptocurrency industry, KuCoin is dedicated to providing top-notch security and reliability. The platform employs state-of-the-art security measures, including advanced encryption protocols, multi-factor authentication, and real-time monitoring systems to ensure the safety of users’ assets. KuCoin’s unwavering focus on security and innovation has solidified its reputation as a trusted and forward-thinking exchange in the global crypto market.

Advertisement
Stake.com

For more information about the KuCoin Broker Program and the new omnibus account structure, please visit KuCoin’s official website.

About KuCoin

Launched in September 2017, KuCoin is a leading cryptocurrency exchange with its operational headquarters in Seychelles. As a user-oriented platform with a focus on inclusiveness and community engagement. It offers over 900 digital assets across Spot trading, Margin trading, P2P Fiat trading, Futures trading, and Staking to its 34 million users in more than 200 countries and regions. KuCoin ranks as one of the top 6 crypto exchanges. KuCoin was acclaimed as “One of the Best Crypto Apps & Exchanges of June 2024” by Forbes Advisor and has been included as one of the top 50 companies in the “2024 Hurun Global Unicorn List”. Learn more at https://www.kucoin.com/ .

Contact Us to Join

Telegram: @KuCoin_Broker

Advertisement
Stake.com

Email: [email protected]

Book a Product Call here.

Logo – https://mma.prnewswire.com/media/2356857/4820578/KuCoin_Horizontal_Green_LOGO_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/kucoin-introduces-omnibus-account-structure-to-enhance-liquidity-for-brokerage-partners-302201693.html

Continue Reading

Trending